Condition: Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma · Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Compassionate Cancer Care Medical Group | Fountain Valley, California, United States | Recruiting |
| Boca Raton Regional Hospital | Boca Raton, Florida, United States | Withdrawn |
| BRCR Medical Center Inc. | Hollywood, Florida, United States | Withdrawn |
| BRCR Medical Center Inc. | Plantation, Florida, United States | Withdrawn |
| Comprehensive Hematology and Oncology | St. Petersburg, Florida, United States | Withdrawn |
| Blood and Marrow Transplant Group of Georgia | Atlanta, Georgia, United States | Recruiting |
| Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| Tulane Cancer Center Office of Clinical Research | New Orleans, Louisiana, United States | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| Christus St. Vincent Regional Cancer Center | Santa Fe, New Mexico, United States | Recruiting |
| Brody School of Medicine at East Carolina University | Greenville, North Carolina, United States | Recruiting |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Withdrawn |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04920617